September 25, 2018

Breast cancer radiotherapy in a single visit provides more convenient option to patients, reduces burden of therapy

Seeds used in radiation therapy are shown, along with a penny to provide scale.

Cross-Canada research team moves image-guided ultrasound system into clinical development

Traditional breast cancer radiation treatment requires multiple hospital visits over a period of weeks or months, which may be onerous to patients who live far from hospitals or in remote communities. An alternative radiotherapy technique, Permanent Breast Seed Implantation (PBSI), requires only a single hospital visit, but it involves the implantation of multiple small radioactive metal pellets into the breast of the patient within millimetres of a target. The procedure to administer this treatment is difficult to plan and complex to execute – impeding the adoption of PBSI in the clinic.

Continue reading – Breast cancer radiotherapy in a single visit provides more convenient option to patients, reduces burden of therapy

September 24, 2018

Breaking down barriers to translation: A case of standardization in digital pathology

Jane Bayani In the lab.

OICR takes part in international multicentre study to standardize promising breast cancer digital pathology test

The Ki67 immunohistochemistry assay is a test that can help evaluate the aggressiveness of breast tumours, predict disease outcomes, monitor cancer progression and identify patients who are more likely to respond to a given therapy. Despite its potential to help patients with breast cancer, the analysis of Ki67 has not been widely adopted in the clinic, mostly due to the lack of standardization across laboratories.

Continue reading – Breaking down barriers to translation: A case of standardization in digital pathology

September 13, 2018

Using imaging to better detect, characterize and monitor prostate cancers

Justin Lau

Sunnybrook researchers develop new magnetic resonance imaging methods to help differentiate between aggressive and non-aggressive prostate cancers

Current needle biopsy techniques have limited accuracy in detecting prostate cancer and determining the tumour’s aggressiveness. New methods are needed to better detect and characterize prostate cancer so that each patient can get the treatment that is most appropriate for them.

Continue reading – Using imaging to better detect, characterize and monitor prostate cancers

September 11, 2018

Portal to access world’s largest database of pediatric genomic data goes live

OICR’s Genome Informatics team plays key role in development of the Gabriella Miller Kids First Data Resource Portal

Toronto (September 11, 2018) – Today, the Gabriella Miller Kids First Data Resource Center (DRC) at the Children’s Hospital of Philadelphia launched the Kids First Data Resource Portal, which will advance personalized medicine for the detection, therapy, and management of childhood cancer and structural birth defects. As the Kids First DRC’s chief outward-facing tool, the Kids First Data Resource Portal serves the needs of a diverse group of patients, researchers, and clinicians partnering to create the world’s largest database of pediatric genomic data, and provides the necessary tools and computational resources for their analysis and interpretation.

Continue reading – Portal to access world’s largest database of pediatric genomic data goes live

September 6, 2018

Q&A with Dr. Christina Yung, OICR’s new Director of Genome Informatics

OICR welcomes Dr. Christina Yung as Director of Genome Informatics. Yung is returning to OICR from the University of Chicago where she led and managed the National Cancer Institute’s Genomic Data Commons (GDC) – a unified data system that promotes the sharing of genomic and clinical data between researchers.

Continue reading – Q&A with Dr. Christina Yung, OICR’s new Director of Genome Informatics

August 22, 2018

Heliotrope: Personalizing cancer treatment decisions

Justin Cook poses for a photo in his office

OICR-developed software tool, Heliotrope, gains attention from the private sector for its potential to analyze large amounts of genomic information and inform clinical decision making

Continue reading – Heliotrope: Personalizing cancer treatment decisions

August 7, 2018

Data integration for the future of precision oncology

CDIC Banner images

Big data are ushering in a new era of individualized cancer care and prevention, but not without conceptual and practical challenges. Canadian advances in genomics will be made by or limited by bioinformatics analytical capacity as well as the ability to store and analyze data in new and more sophisticated ways.

To help realize the potential of genomics research in cancer, the Canadian Data Integration Centre (CDIC) platform, led by OICR, offers third generation bioinformatics and genomics tools to support both functional and clinical genomics research. CDIC is the largest academic cancer informatics program in the country – offering customizable, client-oriented access services for data challenges across diverse research areas.

Continue reading – Data integration for the future of precision oncology

August 3, 2018

Open source in open science: Accelerating cancer research (Part 2)

Part 2 of Open source software

Find part 1 here: Open source in open science: Accelerating cancer research


OICR researchers have contributed to major open source projects available to the global research community in order to accelerate cancer research. Click the link below to read about more of OICR’s open source software projects.

Continue reading – Open source in open science: Accelerating cancer research (Part 2)

August 2, 2018

Ontario centre attracts national attention for probe research, development and commercialization

Centre for Probe Development and Commercialization

The Centre for Probe Development and Commercialization (CPDC) awarded $10.5 million to expand molecular imaging probe work in Ontario

Translating new scientific discoveries into products and moving those products to the market is a challenging process. This is especially the case for highly-regulated medical products such as radiopharmaceuticals – a special class of drugs that are used to accurately diagnose and treat diseases. Over the past decade, the CPDC in Hamilton has been bridging the gap between the innovation and commercialization of radiopharmaceuticals in Ontario and, in turn, reaping benefits for patients and the province’s economy.

Continue reading – Ontario centre attracts national attention for probe research, development and commercialization

August 1, 2018

Open source in open science: Accelerating cancer research (Part 1)

Open source

In the effort to bring better disease prevention and treatment to patients faster, cancer researchers are thinking more creatively about ways to conduct high-quality scientific research. Concerns about the quality, efficiency and reproducibility of research have motivated the open science movement – the growing trend of making data, methods, software and research more accessible to the greater scientific community.

Open source software (OSS), a major component of open science, enables research groups to reduce redundant efforts in software engineering by sharing software code and methods. In addition to improving efficiency, OSS promotes high-quality research by enabling collaboration, and helps make research easier to reproduce by making it more transparent.

Continue reading – Open source in open science: Accelerating cancer research (Part 1)

July 10, 2018

Researchers find early indicators of leukemia in genomes up to 10 years before symptoms surfaced

Immature blood cells in leukemia

Acute myeloid leukemia (AML) progresses quickly and requires treatment soon after diagnosis, but the disease begins long before becoming symptomatic. Early indicators of AML were thought to be indistinguishable from healthy aging. But now, an international group of researchers led in part by Dr. Sagi Abelson, a postdoctoral fellow in the lab of Dr. John Dick at the Princess Margaret Cancer Centre, has discovered distinctive traces of AML in patients up to 10 years before they were diagnosed with the disease.

Continue reading – Researchers find early indicators of leukemia in genomes up to 10 years before symptoms surfaced

June 27, 2018

Healthcare Software Start-Up Ziliomics Financed by FACIT

World-leading genomics cloud computing group builds clinical tool for cancer care in Ontario

TORONTO, ON (June 27, 2018) – Ziliomics Inc., a start-up created by FACIT, received seed financing from the Prospects Oncology Fund. Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer. Together with FACIT’s interim executive management model, the capital advances the development of Heliotrope, Ziliomics’ lead software product, and positions the company for corporate partnerships and additional financing. Financing terms were not disclosed.

Continue reading – Healthcare Software Start-Up Ziliomics Financed by FACIT

Next Page »